David J Miklowitz1, Christopher D Schneck2, Patricia D Walshaw1, Amy S Garrett3,4, Manpreet K Singh3, Catherine A Sugar1,5, Kiki D Chang3. 1. Los Angeles (UCLA) Semel Institute, University of California, Los Angeles, California. 2. Department of Psychiatry, University of Colorado Denver School of Medicine, Aurora, Colorado. 3. Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California. 4. Department of Psychiatry, University of Texas Health Science Center, San Antonio, Texas. 5. Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, California.
Abstract
AIMS: Despite the considerable public health impact of bipolar disorder (BD), no psychosocial interventions have been systematically evaluated in its early prodromal stages. We describe the rationale, design and analytic methods for a 3-site randomized trial of family-focused treatment for youth at high risk (FFT-HR) for BD. METHODS:Participants (ages 9-17 years) have a diagnosis of unspecified BD or major depressive disorder, current mood symptoms and at least one first- or second-degree relative with a lifetime history of BD I or II. Participants are randomly assigned to FFT-HR (12 sessions in 4 months of family psychoeducation and skills training) or enhanced care (EC; 6 individual and family sessions over 4 months), with pharmacotherapy provided as needed. A subset of participants undergo pre- and post-treatment functional MRI (fMRI) scans while performing face-rating and family problem-solving tasks designed to activate corticolimbic circuitry. Independent evaluators assess participants' status every 4 to 6 months for up to 4 years. RESULTS: We hypothesize that FFT-HR will be more effective than EC in reducing the severity of mood symptoms (primary outcome) and the hazard of a first manic episode (secondary) over 4 years. Secondarily, we will explore whether FFT-HR is associated with greater decreases in amygdala activation and increases in dorsolateral, ventrolateral or anterior medial prefrontal cortex activation from pre- to post-treatment. Clinical characteristics of 133 subjects enrolled at baseline are described. CONCLUSIONS: This study will test a novel intervention to reduce the early symptoms of BD, and identify neural and behavioural mechanisms that may help refine future treatments.
RCT Entities:
AIMS: Despite the considerable public health impact of bipolar disorder (BD), no psychosocial interventions have been systematically evaluated in its early prodromal stages. We describe the rationale, design and analytic methods for a 3-site randomized trial of family-focused treatment for youth at high risk (FFT-HR) for BD. METHODS:Participants (ages 9-17 years) have a diagnosis of unspecified BD or major depressive disorder, current mood symptoms and at least one first- or second-degree relative with a lifetime history of BD I or II. Participants are randomly assigned to FFT-HR (12 sessions in 4 months of family psychoeducation and skills training) or enhanced care (EC; 6 individual and family sessions over 4 months), with pharmacotherapy provided as needed. A subset of participants undergo pre- and post-treatment functional MRI (fMRI) scans while performing face-rating and family problem-solving tasks designed to activate corticolimbic circuitry. Independent evaluators assess participants' status every 4 to 6 months for up to 4 years. RESULTS: We hypothesize that FFT-HR will be more effective than EC in reducing the severity of mood symptoms (primary outcome) and the hazard of a first manic episode (secondary) over 4 years. Secondarily, we will explore whether FFT-HR is associated with greater decreases in amygdala activation and increases in dorsolateral, ventrolateral or anterior medial prefrontal cortex activation from pre- to post-treatment. Clinical characteristics of 133 subjects enrolled at baseline are described. CONCLUSIONS: This study will test a novel intervention to reduce the early symptoms of BD, and identify neural and behavioural mechanisms that may help refine future treatments.
Authors: David J Miklowitz; Michael W Otto; Ellen Frank; Noreen A Reilly-Harrington; Stephen R Wisniewski; Jane N Kogan; Andrew A Nierenberg; Joseph R Calabrese; Lauren B Marangell; Laszlo Gyulai; Mako Araga; Jodi M Gonzalez; Edwin R Shirley; Michael E Thase; Gary S Sachs Journal: Arch Gen Psychiatry Date: 2007-04
Authors: Robert L Findling; Eric A Youngstrom; Nora K McNamara; Robert J Stansbrey; Christine A Demeter; Denise Bedoya; Shoshana Y Kahana; Joseph R Calabrese Journal: Bipolar Disord Date: 2005-12 Impact factor: 6.744
Authors: Jon A Shaw; Janice A Egeland; Jean Endicott; Cleona R Allen; Abram M Hostetter Journal: J Am Acad Child Adolesc Psychiatry Date: 2005-11 Impact factor: 8.829
Authors: Esther Mesman; Willem A Nolen; Catrien G Reichart; Marjolein Wals; Manon H J Hillegers Journal: Am J Psychiatry Date: 2013-05 Impact factor: 18.112
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Nick C Patel; Danielle M Patrick; Eric A Youngstrom; Stephen M Strakowski; Melissa P Delbello Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-05 Impact factor: 8.829
Authors: David J Miklowitz; Christopher D Schneck; Manpreet K Singh; Dawn O Taylor; Elizabeth L George; Victoria E Cosgrove; Meghan E Howe; L Miriam Dickinson; Judy Garber; Kiki D Chang Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-01-02 Impact factor: 8.829
Authors: Amy S Garrett; David J Miklowitz; Meghan E Howe; Manpreet K Singh; Tenah K Acquaye; Christopher G Hawkey; Gary H Glover; Allan L Reiss; Kiki D Chang Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2014-10-02 Impact factor: 5.067
Authors: Xavier Estrada-Prat; Anna R Van Meter; Ester Camprodon-Rosanas; Santiago Batlle-Vila; Benjamin I Goldstein; Boris Birmaher Journal: Bipolar Disord Date: 2019-05-15 Impact factor: 6.744
Authors: Marc J Weintraub; Christopher D Schneck; Patricia D Walshaw; Kiki D Chang; Manpreet K Singh; David A Axelson; Boris Birmaher; David J Miklowitz Journal: J Psychiatr Res Date: 2020-01-25 Impact factor: 4.791
Authors: Marc J Weintraub; Christopher D Schneck; Patricia D Walshaw; Kiki D Chang; Aimee E Sullivan; Manpreet K Singh; David J Miklowitz Journal: J Affect Disord Date: 2020-08-13 Impact factor: 4.839
Authors: David J Miklowitz; Christopher D Schneck; Patricia D Walshaw; Manpreet K Singh; Aimee E Sullivan; Robert L Suddath; Marcy Forgey Borlik; Catherine A Sugar; Kiki D Chang Journal: JAMA Psychiatry Date: 2020-05-01 Impact factor: 21.596
Authors: Amy S Garrett; Kiki D Chang; Manpreet K Singh; Casey C Armstrong; Patricia D Walshaw; David J Miklowitz Journal: Bipolar Disord Date: 2021-01-26 Impact factor: 5.345
Authors: Anna R Van Meter; Danella M Hafeman; John Merranko; Eric A Youngstrom; Boris B Birmaher; Mary A Fristad; Sarah M Horwitz; L Eugene Arnold; Robert L Findling Journal: J Am Acad Child Adolesc Psychiatry Date: 2020-10-08 Impact factor: 13.113
Authors: Manpreet K Singh; Akua F Nimarko; Amy S Garrett; Aaron J Gorelik; Donna J Roybal; Patricia D Walshaw; Kiki D Chang; David J Miklowitz Journal: J Am Acad Child Adolesc Psychiatry Date: 2020-08-01 Impact factor: 8.829